Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis

Lupus

Volumn 22, Issue 7, 2013, Pages 727-732

  Kittanamongkolchai, W ^a   Rukrung, C ^a   Supasiri, T ^a   Lertjirachai, I ^a   Somparn, P ^a   Chariyavilaskul, P ^a   Avihingsanon, Y ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

glomerulonephritis; immunosuppression; Lupus nephritis; mycophenolate; therapeutic drug monitoring

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; SIDE EFFECT; THRUSH; TINEA VERSICOLOR; TREATMENT RESPONSE; URINARY TRACT INFECTION;

GLOMERULONEPHRITIS; IMMUNOSUPPRESSION; LUPUS NEPHRITIS; MYCOPHENOLATE; THERAPEUTIC DRUG MONITORING;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879238114     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313486949     Document Type: Article

References (15)

1. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005 ; 16: 1076-1084
2. Ginzler EM, Aranow C. Mycophenolate mofetil in lupus nephritis. Lupus. 2005 ; 14: 59-64
3. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112
4. van Gelder T, Tedesco Silva H, de Fijter JW, Budde K, Kuypers D, Arns W, et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation. 2010 ; 89: 595-599
5. van Gelder T. TDM for mycophenolic acid at no extra cost. Transplantation. 2010 ; 89: 1176-1177
6. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004 ; 4: 1079-1083
7. Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007 ; 7: 2496-2503
8. Neumann I, Haidinger M, Jager H, Grutzmacher H, Griesmacher A, Muller MM, et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol. 2003 ; 14: 721-727
9. Roland M, Barbet C, Paintaud G, Magdelaine-Beuzelin C, Diot E, Halimi JM, et al. Mycophenolate mofetil in patients with systemic lupus erythematosus: A prospective pharmacokinetic study. Lupus. 2009 ; 18: 441-447
10. Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, et al. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: An observational cohort study. Arthritis Res Ther. 2010 ; 12: R217 - R217
11. Lertdumrongluk P, Somparn P, Kittanamongkolchai W, Traitanon O, Vadcharavivad S, Avihingsanon Y. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int. 2010 ; 78: 389-395
12. Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 2010 ; 62: 2047-2054
13. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant. 2008 ; 23: 3514-3520
14. van Gelder T, Domke I, Engelmayer J, de Fijter H, Kuypers D, Budde K, et al. Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. Ther Drug Monit. 2009 ; 31: 218-223
15. Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: Systematic review and meta-analysis. Medicine. 2010 ; 89: 227-235